<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Nobunari Sasaki et al.|Cancer Discovery|2024Cited by 98
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Himisha Beltran, Xiaofei Wang et al.|JNCI Journal of the National Cancer Institute|2023Cited by 9
Data from <i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Haritha Mathsyaraja et al.|Unknown|2024Cited by 1
Supplementary Table S1 from <i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Haritha Mathsyaraja et al.|Unknown|2024Cited by 0
Supplementary figure S3 from <i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Haritha Mathsyaraja et al.|Unknown|2024Cited by 0